Please use this identifier to cite or link to this item:
Title: Lipoxin A4 Attenuates Constitutive and TGF-β1-Dependent Profibrotic Activity in Human Lung Myofibroblasts
Authors: Roach, Katy M.
Feghali-Bostwick, C. A.
Amrani, Yassine
Bradding, Peter
First Published: 14-Aug-2015
Publisher: American Association of Immunologists
Citation: Journal of Immunology, 2015, 195 (6), pp. 2852-2860
Abstract: Idiopathic pulmonary fibrosis (IPF) is a common, progressive, and invariably lethal interstitial lung disease with no effective therapy. The key cell driving the development of fibrosis is the myofibroblast. Lipoxin A[subscript: 4] (LXA[subscript: 4]) is an anti-inflammatory lipid, important in the resolution of inflammation, and it has potential antifibrotic activity. However, the effects of LXA[subscript: 4] on primary human lung myofibroblasts (HLMFs) have not previously been investigated. Therefore, the aim of this study was to examine the effects of LXA[subscript: 4] on TGF-β1-dependent responses in IPF- and nonfibrotic control (NFC)-derived HLMFs. HLMFs were isolated from IPF and NFC patients and grown in vitro. The effects of LXA[subscript: 4] on HLMF proliferation, collagen secretion, α-smooth muscle actin (αSMA) expression, and Smad2/3 activation were examined constitutively and following TGF-β1 stimulation. The LXA[subscript: 4] receptor (ALXR) was expressed in both NFC- and IPF-derived HLMFs. LXA[subscript: 4] (10[superscript: -10] and 10[superscript: -8] mol) reduced constitutive αSMA expression, actin stress fiber formation, contraction, and nuclear Smad2/3, indicating regression from a myofibroblast to fibroblast phenotype. LXA[subscript: 4] also significantly inhibited FBS-dependent proliferation and TGF-β1-dependent collagen secretion, αSMA expression, and Smad2/3 nuclear translocation in IPF-derived HLMFs. LXA[subscript: 4] did not inhibit Smad2/3 phosphorylation. In summary, LXA[subscript: 4] attenuated profibrotic HLMF activity and promoted HLMF regression to a quiescent fibroblast phenotype. LXA[subscript: 4] or its stable analogs delivered by aerosol may offer a novel approach to the treatment of IPF.
DOI Link: 10.4049/jimmunol.1500936
ISSN: 0022-1767
eISSN: 1550-6606
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2015 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
J Immunol-2015-Roach-jimmunol.1500936.pdfPublished (publisher PDF)1.46 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.